Appoints Preston S. Klassen, M.D., as President and Head of Research & Development
Curtis A. Monnig, Ph.D., named Vice President of CMC
SAN DIEGO, June 12, 2023 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced the appointment of Preston S. Klassen M.D., M.H.S., to President and Head of Research and Development. Dr. Klassen brings over 20 years of experience in leadership roles in both large and small biopharmaceutical companies. In addition, the Company announced the appointment of Curtis A. Monnig, Ph.D., to Vice President of CMC.
Read more at prnewswire.com